Abstract CT223: AACR Adaptive Biomarker-Driven Organ Preservation Trial in GE Adenocarcinomas (AACR-ADOPT-GEA)
Elena Elimova(Princess Margaret Cancer Centre), Patricia LoRusso, Denise Gallagher(American Association For Cancer Research), Samuel J. Klempner(Broad Institute), J AJANI(The University of Texas MD Anderson Cancer Center), Eric H. Rubin(Rutgers Cancer Institute), Jan D. Baranski(American Association For Cancer Research), Scott A. Boerner, Sienna M. Durbin(Global Cancer Institute), Kurt Schalper, Ronan A. McLaughlin(Princess Margaret Cancer Centre), Huh Won Jae, Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Zev Wainberg(University of California, Los Angeles), Matthew R. Strickland(Massachusetts General Hospital), Yuan Ying(The University of Texas MD Anderson Cancer Center), L SIU(Princess Margaret Cancer Centre)
Cited by 0
Related Papers
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
|Clinical Cancer Research|2021|369
Geometric control of vascular networks to enhance engineered tissue integration and function
|Proceedings of the National Academy of Sciences|2013|269
Cancer Vulnerabilities Unveiled by Genomic Loss
|Cell|2012|240
Bioactive hydrogels made from step-growth derived PEG–peptide macromers
|Biomaterials|2010|214
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
|Nature Medicine|2023|197